TheEdgeResearch
Home / Stocks / SRTOY

Sartorius Stedim Biotech S.A. (SRTOY)

OTC Healthcare Medical - Instruments & Supplies
$23.86 ▼ -2.35%
Market Cap
$232.20B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Beta
1.14
52-Wk Range
17.25-26.54
CEO
Rene Faber
Country
FR
Currency
USD

Sartorius Stedim Biotech S.A. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Aubagne, PAC, FR. The stock last traded at $23.86, down 2.35% on the session, giving a market capitalisation of $232.20B. On trailing twelve-month figures it carries a trailing P/E of 66.05, a net margin of 10.6%. Its beta of 1.14 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
66.05
Price / Sales
7.01
Price / Book
4.90
EV / EBITDA
26.20
Gross margin
44.6%
Operating margin
19.4%
Net margin
10.6%
Return on equity
—
Debt / equity
0.53
Current ratio
1.22
Dividend yield
0.3%
Payout ratio
20.7%
Company profile
Exchange
Other OTC
Employees
10,265
IPO date
2022-02-09
Headquarters
Aubagne, PAC, FR
About Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.

Comparable companies

Sartorius Stedim Biotech S.A. is most often compared with the following Healthcare names:

AVTRBLFSDHRLZAGYMKKGYRGENSOAGYSSSGYTCGGYWST
More research on SRTOY
SRTOY technical analysis SRTOY TheEdge Score Compare against peers
Open full interactive analysis & DCF →